mProX™ Human SLAMF7 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human SLAMF7 Stable Cell Line (S01YF-1023-PY289). Click the button above to contact us or submit your feedback about this product.
Cameron Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Alex Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Reduced levels of proinflammatory cytokines were observed in RAW-SLAMF7 cells.
A construction was undertaken to generate RAW264.7 cells that were stably expressed with SLAMF7 (termed RAW-SLAMF7), along with a set of control RAW-vector cells. The examination of mRNA levels for Tnf, Il1b, and Il6 in RAW-SLAMF7 cells in comparison to RAW vector cells was conducted at three distinct time points: 0 hours, 6 hours, and 12 hours post-LPS stimulation.
Ref: Wu, Yongjian, et al. "SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis." The Journal of Clinical Investigation 133.6 (2023).
Pubmed: 36749634
DOI: 10.1172/JCI150224
Research Highlights
Groh, M. et al. "IgG4-related disease: A proteiform pathology with frequent chest manifestations." Revue des maladies respiratoires, 2023.
IgG4-related disease (IgG4-RD) was first identified in the early 2000s, but its diverse symptoms had been previously documented under various terms. These symptoms are characterized by the presence of oligoclonal plasma cells and fibrosis associated with IgG4.
Groh, M. et al. "IgG4-related disease: A proteiform pathology with frequent chest manifestations." Revue des maladies respiratoires, 2023.
Pubmed:
37858433
DOI:
10.1016/j.rmr.2023.10.001
Lin, Hui; Yan, Hai. "Newest Advances in Diagnosis and Treatment of Plasmablastic Lymphoma --Review." Zhongguo shi yan xue ye xue za zhi, No publication year..
Plasmablastic lymphoma (PL/PBL) is a rare and highly aggressive type of lymphoma with a poor prognosis. Strict diagnostic and therapeutic criteria for PBL are lacking. Along with traditional plasma cell markers, SLAMF7 may serve as a valuable supplement for PBL diagnosis. High-dose chemotherapy in combination with bortezomib or lenalidomide shows promise as a first-line treatment. For second-line therapy, emerging treatments such as immune checkpoint inhibitors, CAR-T cell therapy, and novel targeted agents have shown potential to improve survival rates for PBL patients. This review focuses on the diagnosis, differentiation, first-line treatment, and management of relapsed/refractory PBL to further advance understanding of this disease.
Lin, Hui; Yan, Hai. "Newest Advances in Diagnosis and Treatment of Plasmablastic Lymphoma --Review." Zhongguo shi yan xue ye xue za zhi, No publication year..
Pubmed:
37846723
DOI:
10.19746/j.cnki.issn.1009-2137.2023.05.055
